GEN Exclusives

More »

GEN News Highlights

More »
Mar 16, 2011

MorphoSys and BI Sign Process Development and Manufacturing Deal for CLL mAb

  • Boehringer Ingelheim (BI) is to provide MorphoSys with process development and additional manufacturing for its early clinical-stage chronic lymphocytic leukemia candidate MOR208 and other drugs. MOR208 is an in-licensed antibody currently undergoing Phase I evaluation in the U.S. by MorphoSys’ partner Xencor.

    “Adding an additional supplier to our proprietary development setup will help to prevent any bottlenecks in clinical trial supply in the years ahead,” notes Marlies Sprol, Ph.D., MorphoSys CSO. “Additionally, establishing a commercial manufacturing process with BI early in the development of MOR208 will clearly increase the value of this program.”

    MOR208 (formerly XmAb®5574) is a humanized CD19-targeting monoclonal antibody in development for the potential treatment of B-cell malignancies and autoimmune diseases. MorphoSys negotiated an exclusive worldwide license to the candidate from Xencor in June 2010. Under terms of the deal, Xencor received $13 million up front. The firms are collaborating on the Phase I study in CLL patients. If the study is successful, MorphoSys will shoulder all further clinical development of the antibody.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Block That Microbiome Metaphor!

Which way of thinking about the microbiome would best integrate the virome’s contributions?